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Oral Presentations S175and exposure to TBI 6CRT. These factors may contribute to
a higher risk of early CVD morbidity and mortality suggesting
that screening and management of modifiable CVD risk factors
should be initiated in HCT survivors.
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CT, allogeneiMean p-value‡ Mean p-value‡ Mean p-value‡ MeanHeight (cm)* 162.1 <.001 159.8 <.001 161.3 <.001 169.8Weight (kg)* 62.0 0.002 59.7 0.002 59.9 <.001 69.9BMI (kg/m^2)* 23.2 0.31 23.4 0.400 22.7 0.064 24.0Waist Circumference
(cm)*78.8 0.646 79.4 0.584 77.2 0.185 79.6PFM, DXA* 33.6 <.001 33.8 0.012 32.3 0.007 28.6Lean Body Mass(kg)* 37.6 <.001 35.0 <.001 35.8 <.001 46.9Systolic BP (mmHg)† 112.2 0.245 116.4 0.509 113.6 0.121 114.3Diastolic BP (mmHg)† 64.9 0.919 65.5 0.615 65.2 0.785 64.8Total Cholesterol
(mg/dL)†170.7 <.001 192 <.001 167.2 0.009 150.6LDL-Cholesterol
(mg/dL)†97.6 0.045 107.7 0.008 93.3 0.16 88.1HDL-Cholesterol
(mg/dL)†43.4 0.295 38.8 0.006 45.2 0.797 45.2Triglycerides (mg/dL)† 154.4 <.001 252.1 0.002 146.9 0.008 82.9Glucose (mg/dL)† 85.2 0.573 90.2 0.04 83.9 0.998 84.4Insulin (mU/L)† 14 0.005 19.2 0.002 12 0.092 9.8Mlbm
(mg/LBM(kg)/min)†,**9.8 0.043 7.2 0.003 10.6 0.359 11.5*adjusted for age-at-study, sex, race, and Tanner.
†adjusted for age-at-study, sex, race, and Tanner, and PFM.
‡P-values for comparison to Controls.
**low Mlbm represents IR.62
RISK FACTORS FOR LATE CARDIOVASCULAR MORBIDITY AND
MORTALITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION
Chow, E.J.1,2,3, Lee, S.J.1,2, Friedman, D.L.4, Cushing-Haugen, K.L.1,
Martin, P.J.1,2, Mueller, B.A.1,2, Baker, K.S.1,2,3 1Fred Hutchinson Can-
cer Research Center, Seattle, WA; 2University of Washington, Seattle,
WA; 3Seattle Children’s Hospital, Seattle, WA; 4Vanderbilt University,
Nashville, TN
Purpose: To examine the effect of pre-transplant treatment and
transplant related-risk factors for late cardiovascular (CV) disease
following hematopoietic cell transplantation (HCT).
Methods: Nested case-cohort study. All 2 yr HCT survivors who
were Washington State residents treated at the Fred Hutchinson
Cancer Research Center from 1985-2006 (n 5 1491; 56% alloge-
neic, 44% autologous) were linked to the state’s hospital discharge
and death registries beginning 2 yrs after HCT (1987-2008). Deathses Associate
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c/autologous dand hospitalizations due to selected CV diagnoses (ischemic heart
disease, cardiomyopathy, dysrhythmia, stroke and other vascular dis-
ease) and related conditions (hypertension, dyslipidemia, diabetes,
renal disease/dialysis) were identified. Relationships (hazard ratios,
HR) among treatment risk factors and CV outcomes were examined
between affected survivors (cases, n 5 436) and a randomly selected
subset of the remaining HCT cohort (n 5 371).
Results: Among these 807 survivors, median age at HCT was 41 (0-
73) yrs and time to event was 5 (2-24) yrs. Individual CV events in-
cluded: 39 CV-related deaths, 56 ischemic heart disease, 80 cardiomy-
opathy, 109 dysrhythmia, 33 stroke, and 52 other vascular disease. In
multivariable models, survivors with cumulative anthracycline expo-
sures $ 300 mg/m2 were more likely to experience CV death (HR
2.8, 95% CI 1.0-7.6), cardiomyopathy (HR 2.1, 95% CI 1.0-4.4),
and dysrhythmia (HR 1.9, 95% CI 1.1-3.3). The association between
anthracycline dose and CV outcomes appeared greater following allo-
geneic than autologous HCT. Allogeneic HCT also was associated
with increased risk of hypertension (HR1.6, 95%CI1.1-2.3), with un-
related donorHCTand chronic graft versus host disease (GVHD) be-
ing significant risk factors. Total body irradiation and chest radiation
were not independently associated with anyCVoutcome. In sub-anal-
yses, survivors with dyslipidemia 1 yr after HCT had an increased risk
of subsequent ischemic heart disease (HR 8.9, 95% CI 3.1-25.9), and
those with both dyslipidemia and hypertension 1 yr after HCT also
had increased risk of subsequent diabetes (HR 4.3, 95% CI 1.6-11.2).
Conclusions: Increased exposure to pre-HCT anthracyclines was
associated with multiple adverse CV outcomes after HCT, including
CV death. HCTwith unrelated donors and chronic GVHDwere as-
sociated with increased risk of hypertension, but otherHCT-specific
exposures were not consistently associated with additional risk of CV
morbidity.63
EVALUATION OF SCALES CORRELATED WITH CLINICIAN AND PATIENT-
PERCEIVED SYMPTOM CHANGE IN OCULAR GRAFT-VERSUS-HOST DIS-
EASE: RESULTS FROM THE CHRONIC GVHD CONSORTIUM
Inamoto, Y.1, Kurland, B.F.1, Chai, S.1, Heffernan,M.J.1, Martin, P.J.1,
Flowers, M.E.D.1, Carpenter, P.A.1, Cutler, C.2, Jacobsohn, D.3,
Jagasia, M.4, Johnston, L.5, Vogelsang, G.B.6, Pavletic, S.Z.7, Lee, S.J.1
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2Dana-Farber
Cancer Institute, Boston, MA; 3Children’s National Medical Center,
Washington, DC; 4Vanderbilt University Medical Center, Nashville,
TN; 5Stanford University Medical Center, Stanford, CA; 6Johns Hopkins
Hospital, Baltimore, MD; 7National Cancer Institute, National Institutes
of Health, Bethesda, MD
Measurement scales used to rate the symptomchange in ocular graft-
versus-host disease (GVHD) have not been validated for use in clinical
trials.
Methods: We compared clinician and patient perceptions of eye
symptom changes based on serial clinician or patient-reportedd with Treatment Exposures, Hazard Ratios (95% CI)
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S176 Oral Presentationsmeasurement scales in a prospective multi-center cohort of 243 pa-
tients (median age 51,range 6-79) with chronic GVHD. An 8-point
scale of perceived change was used to score changes that were ‘‘com-
pletely gone (1)’’ to ‘‘very much worse (8)’’, with generalized estimat-
ing equations (GEE) to account for multiple visits per patient.
Clinician and patient ratings of eye involvement and change in ocular
GVHD activity were compared using kappa statistics. Clinic visits
were scheduled every 3-6 months. Measurement scales evaluated in-
clude theNIH eye score reported by clinicians (1 item, 0-3), patient-
reported global rating of eye symptom (1 item, 0-10), patient-re-
ported Lee symptom scale (2 items, 0-100), patient-reported ocular
surface disease index (OSDI, 12 items, 0-100) and the measured
Schirmer’s test.
Results:At enrollment, eye involvementwas reported by clinicians for
117 patients (48%) and self-reported by 148 patients (61%)(kappa 5
0.37, fair agreement). Clinician-rated change was examined for 152
paired visits when clinicians had reported eye involvement. Patient-
rated change was examined for 174 paired visits when patients had re-
ported eye involvement. Both clinicians and patients tended to report
symptom change as stable (60% and 57%, respectively), with improve-
ment (34% and 35%) more likely than worsening (6% and 8%), but
the agreement between evaluators was fair (kappa 5 0.36). Testing
correlations of change in measures between adjacent visits with per-
ceived change at the follow-up visit, changes in the NIH eye score
were strongly related to changes perceived by both clinicians and pa-
tients (Table). Changes in patient-reported measures (global rating,
Lee scale and OSDI) were strongly associated with patient-perceived
changes but were less strongly associated with clinician-perceived
changes. Changes in measures by Schirmer’s test were associated
with changes perceived by clinicians but not by patients.
Conclusion: Concordance between clinician and patient ratings of
eye involvement and change in eye symptoms was fair. Our results
support the use of theNIH eye score as a sensitivemeasure of change
in ocular GVHD since it correlates with both clinician and patient-
perceived symptom change.
Table 1. Relationship of perceived change in ocular GVHD
symptoms between adjacent visits by clinicians and patients,
with longitudinal change in measurement scales
Clinician-perceived Patient-perceived
change* change*Measurement
scaleClinically
meaningful
change in
measure N Estimate† P N Estimate† PNIH eye score 1 point 180 1.23 <0.001 174 0.48 <0.001
Patient-reported
global rating
of eye symptom2 points 138 0.26 0.03 169 0.50 <0.001Lee symptom
eye score15 points 141 0.21 0.03 173 0.42 <0.001OSDI 10 points 132 0.17 0.04 164 0.31 <0.001
Schirmer’s test‡ -5 mm 178 0.26 0.005 172 -0.06 0.45*Perceived change in symptoms between adjacent visits: 1-8 scale.
†Perceived change in symptoms associated with longitudinal change in
measure (Example: A 5 mm decrease in Schirmer’s test is associated
with a clinician-perceived 0.26 worsening in ocular GVHD.).
‡Worse value of both eyes.64
MULTIPLE NON-MALIGNANT COMPLICATIONS AFTER HEMATOPOIETIC
CELL TRANSPLANTATION ARE ASSOCIATED WITH POOR QUALITY OF
LIFE
Khera, N., Storer, B., Flowers, M.E.D., Carpenter, P.A., Inamoto, Y.,
Martin, P.J., Lee, S.J. Fred Hutchinson Cancer Research Center, Seattle,
WA
Background and Methods: As the number of hematopoietic cell
transplant (HCT) survivors increases, there is a growing need to un-
derstand the delayed nonmalignant complications which may not belife threatening but are still severe enough to significantly impair
quality of life (QOL), contributing to long-term morbidity after
HCT. The study was conducted to determine the incidence of non-
malignant late effects. All incoming medical records and annual self-
reported questionnaires from adult patients transplanted between 1/
04 through 6/09 at Fred Hutchinson who survived at least 1 year af-
ter HCT were screened for nonmalignant complications. We calcu-
lated the cumulative incidence of 15 specific late effects including
musculoskeletal (AVN, joint replacement, osteoporosis), endocrine
(DM, thyroid disease, adrenal insufficiency), cardiovascular (CAD,
CVA, DVT), organ specific (obstructive or restrictive lung disease/
dialysis/organ transplant) andmiscellaneous (peripheral neuropathy,
iron overload, suicide/suicide attempt). Pre-transplant prevalence of
these conditions was determined in a random sample of 200 cases
from the study population.
Results: The study included 1087 survivors with median age at
HCT of 53 years (range 21-78) and a median follow-up period
from HCT of 37 months (range 12-77). 60% of the subjects
were males, 84% were White and 54% received allogeneic HCT.
In the allogeneic group, the cumulative incidence of chronic
GvHD at 5 years was 60%. The cumulative incidence (CI) of any
late nonmalignant effect at 5 years after HCT was 70% in autolo-
gous and 85% in allogeneic groups, with 14% of autologous and
38% of allogeneic recipients having $ 3 late effects. Peripheral
neuropathy was common in both autologous and allogeneic recip-
ients (CI 37% and 28% respectively) but also had a high pre-trans-
plant prevalence (23%). In the autologous group, the two most
common other late effects were thyroid disease (20%) and osteopo-
rosis (11%). In allogeneic recipients, lung disease (39%) and DM
(29%) were the most common complications. The effect of these
complications on physical and mental functioning, work status
and limitations was assessed in a subgroup who completed an
annual self-reported assessment. (Table)
Conclusion: The adverse impact of these complications on QOL
and long- term outcomes in HCT survivors underscores the need
for greater attention to the prevention and management of these
complications and continued close follow-up of this group.
Table 1. Relationship of QOLmeasures to late effects in 544 1-
year survivors
Number of prior/contemporaneous late effects0
(n5155)1
(n5154)2
(n5107)$3
(n5128)P
value R2Karnofsky score
mean(SD)
88.0 (12.4) 86.7 (13.0) 87.4 (11.9) 81.7 (13.4) 0.00021 2.6%Work Limitations,n (%)No Limits 56 (38) 58 (39) 34 (34) 27 (22)Limited a little 53 (36) 52 (35) 41 (41) 49 (40)Limited a lot 23 (16) 18 (12) 13 (12) 24 (20)Limited completely 15 (10) 19 (13) 11(11) 22(18) 0.0042 NAUsual work now, n (%)Full time work/student 61 (40) 43 (28) 36 (34) 24 (19)Part- time
work/student21 (14) 21 (14) 13 (12) 19 (15)Work at home 18 (12) 10 (7) 14 (13) 9 (7)Retired 35 (23) 63 (41) 35 (33) 58 (45)Other 17 (11) 16 (10) 9 (8) 18 (14) 0.0033 NAPCS 12, n (%)¶>50 67 (45) 62 (43) 36 (35) 24 (21)40-50 30 (20) 27 (19) 33 (32) 20 (17)<40 51 (34) 54 (38) 33 (32) 71 (62) <0.00012 NAMCS 12, n (%)¶>50 107 (72) 113 (79) 88 (86) 78( 68)40-50 25 (17) 20 (14) 7 (7) 17 (15)<40 16 (11) 10 (7) 7 (7) 20 (17) 0.622 NA1p-trend from linear regression model, 2 p-trend from proportional
odds model, 3 chi-squared test, ¶ Physical and mental component score
as derived from SF-12
